Genelux Corp
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Genelux Corp
Did you know?
Capital expenditures increased by 188% from FY24 to FY25.
Current Price
$2.85
+4.01%Profile
Valuation (TTM)
Market Cap$108.45M
P/E-3.37
EV—
P/B9.39
Shares Out38.05M
P/Sales—
Revenue$0.00
EV/EBITDA—
Genelux Corp (GNLX) Stock Analysis
Market Cap$108.45M
Current Price$2.85
P/E Ratio-3.37
Forward P/E—
PEG Ratio0.44
EPS$-0.86
Book Value$0.30
P/B Ratio9.39
GNLX Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 4M
Revenue
—
FY20
—
FY21
11M
FY22
—
FY23
—
FY24
—
FY25
Net Income
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
GNLX 52-Week Range
$2.30
$8.24
50-Day MA: $2.64200-Day MA: $3.81
Did you know?
Currently near its 52-week low — in the bottom 9% of its range.
Genelux Corp (GNLX) Financial Summary
Genelux Corp (GNLX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $2.85 with a market capitalization of $108.45M.
Key valuation metrics include a P/E ratio of -3.37, price-to-book ratio of 9.39, and EPS of $-0.86. and return on equity of -278.5%.
GNLX Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $108.45M |
| P/E Ratio | -3.37 |
| EPS | $-0.86 |
| P/B Ratio | 9.39 |
| Return on Equity | -278.5% |
| Debt/Equity | 0.15 |
GNLX Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY20 | $0.00 | $-13.64M |
| FY21 | $0.00 | $-16.38M |
| FY22 | $11.07M | $-5.21M |
| FY23 | $170000.00 | $-28.30M |
| FY24 | $0.00 | $-29.87M |
| FY25 | $0.00 | $-32.15M |
About Genelux Corp
Genelux Corp
GNLX Free Cash Flow
Genelux Corp generated $-26.37M in trailing twelve-month free cash flow, representing an FCF yield of -24.31%. This low FCF yield may reflect heavy reinvestment or growth spending.
GNLX Shares Outstanding
Genelux Corp has 0.04 billion shares outstanding at a share price of $2.85, giving it a market capitalization of $108.45M.